{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T20:56:26Z","timestamp":1767905786203,"version":"3.49.0"},"reference-count":24,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Indolent cutaneous B-cell lymphomas (CBCL) are a rare disease for which the therapeutic recommendations are based on clinical reports. Recommendations for solitary lesions include surgery or irradiation. However, the high relapse rates may require less invasive repeatable therapy. This study seeks to retrospectively assess the efficacy of intralesional rituximab (ILR) for indolent CBCL when compared with intravenous rituximab (IVR). Patients treated for indolent CBCL with ILR or IVR at the Division of DermatoOncology of the University Hospital Heidelberg were eligible for this study. Characteristics of lymphoma, treatment response, and adverse events were assessed. Twenty-one patients, 67% male at a median age of 52 (range 17\u201380), were included. Nineteen (90%) had only localized lymphoma (stage T1 and T2). Complete response was achieved in 92% (11\/12) of ILR after a median of one cycle (three injections) and 78% (7\/8) of IVR patients after a median of six cycles. Half of ILR patients and 78% of IVR patients showed relapse after a median of 15 and 23 months, respectively. Adverse reactions were usually mild and were limited to the first injection of ILR. One patient with IVR contracted a pulmonary infection. ILR may be an alternative to the intravenous administration of rituximab for localized indolent CBCL.<\/jats:p>","DOI":"10.3390\/cancers14194787","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:07:43Z","timestamp":1665187663000},"page":"4787","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment of Indolent Cutaneous B-Cell Lymphoma with Intralesional or Intravenous Rituximab"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1506-0191","authenticated-orcid":false,"given":"Christian","family":"Menzer","sequence":"first","affiliation":[{"name":"Division of DermatoOncology, Department of Dermatology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Rendon","sequence":"additional","affiliation":[{"name":"Division of DermatoOncology, Department of Dermatology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7575-6230","authenticated-orcid":false,"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[{"name":"Division of DermatoOncology, Department of Dermatology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"329.e1","DOI":"10.1016\/j.jaad.2013.06.012","article-title":"Primary cutaneous B-cell lymphomas: Part I. Clinical features, diagnosis, and classification","volume":"69","author":"Pulitzer","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","article-title":"European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas","volume":"112","author":"Senff","year":"2008","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"343.e1","DOI":"10.1016\/j.jaad.2013.06.011","article-title":"Primary cutaneous B-cell lymphomas: Part II. Therapy and future directions","volume":"69","author":"Querfeld","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","first-page":"438","article-title":"Rituximab in the treatment of primary cutaneous B-cell lymphoma: A Review","volume":"105","year":"2014","journal-title":"Actas Dermosifiliogr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1016\/j.jaad.2012.07.010","article-title":"Cryotherapy for primary cutaneous B-cell lymphoma","volume":"67","author":"Myskowski","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kollipara, R., Hans, A., Hall, J., and Lisle, A. (2015). A case report of primary cutaneous marginal zone lymphoma treated with intralesional steroids. Dermatol. Online J., 21.","DOI":"10.5070\/D3218028432"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jaad.2013.11.019","article-title":"Treatment of indolent primary cutaneous B-cell lymphomas with subcutaneous interferon-alfa","volume":"70","author":"Vandersee","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jaad.2008.08.005","article-title":"Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab","volume":"59","author":"Morales","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2133.2012.10902.x","article-title":"Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: An epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma","volume":"167","author":"Santiago","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/CCO.0000000000000060","article-title":"Recent advances in primary cutaneous B-cell lymphomas","volume":"26","author":"Vermeer","year":"2014","journal-title":"Curr. Opin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3389\/fonc.2020.01133","article-title":"The Safety of Radiotherapy in the Treatment of Primary Cutaneous B-Cell Lymphoma: A Multidisciplinary Systematic Review","volume":"10","author":"Tagliaferri","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","article-title":"TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and S\u00e9zary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1080\/0284186X.2021.1956689","article-title":"Primary cutaneous indolent B-cell lymphomas\u2014A retrospective multicenter analysis and a review of literature","volume":"60","author":"Sobas","year":"2021","journal-title":"Acta Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2004.08.044","article-title":"Primary Cutaneous B-Cell Lymphoma Treated with Radiotherapy: A Comparison of the European Organization for Research and Treatment of Cancer and the WHO Classification Systems","volume":"22","author":"Smith","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/bjd.19490","article-title":"Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphoma","volume":"184","author":"Chirico","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3389\/fonc.2020.00651","article-title":"Primary Cutaneous B-Cell Lymphomas: An Update","volume":"10","author":"Vitiello","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s40257-022-00704-0","article-title":"Update in Diagnosis and Management of Primary Cutaneous B-Cell Lymphomas","volume":"23","author":"Krenitsky","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"adv00383","DOI":"10.2340\/00015555-3746","article-title":"Long-term Therapeutic Success of Intravenous Rituximab in 26 Patients with Indolent Primary Cutaneous B-cell Lymphoma","volume":"101","author":"Porkert","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/archderm.136.3.374","article-title":"Intralesional Therapy with Anti-CD20 Monoclonal Antibody Rituximab in Primary Cutaneous B-Cell Lymphoma","volume":"136","author":"Heinzerling","year":"2000","journal-title":"Arch. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/cc11304","article-title":"Clinical review: Serious adverse events associated with the use of rituximab\u2014A critical care perspective","volume":"16","author":"Kasi","year":"2012","journal-title":"Crit. Care"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/annrheumdis-2021-220781","article-title":"SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity","volume":"80","author":"Mrak","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jdcr.2016.07.006","article-title":"Intralesional rituximab for cutaneous manifestations of systemic B-cell lymphoma","volume":"2","author":"Thibeault","year":"2016","journal-title":"JAAD Case Rep."},{"key":"ref_24","unstructured":"(2022, August 21). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)\u2014Primary Cutanous Lymphoma Version 2. 2022. National Comprehensice Cancer Network. Updated 8 June 2022. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/primary_cutaneous.pdf."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/19\/4787\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:44:19Z","timestamp":1760143459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/19\/4787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":24,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["cancers14194787"],"URL":"https:\/\/doi.org\/10.3390\/cancers14194787","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]}}}